4-(4-hydroxy-phenoxy)-butyric acid ethyl ester | 166954-96-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-(4-hydroxy-phenoxy)-butyric acid ethyl ester
• 英文别名: 4-(4-formylphenoxy)butanoate；ethyl 4-(4-hydroxyphenoxy)butanoate；ethyl 4-(4-hydroxyphenoxy)butyrate
• CAS: 166954-96-7
• 化学式: C₁₂H₁₆O₄
• 分子量: 224.257
• InChiKey: HBZGVMJZSWZNPE-UHFFFAOYSA-N

物化性质

• 沸点：
  367.9±22.0 °C(Predicted)
• 密度：
  1.133±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-hydroxy-phenoxy)-butyric acid ethyl ester 在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 4.0h， 以98%的产率得到4-(4-羟基-苯氧基)-丁酸
  参考文献：
  名称：

  Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models

  摘要：

  The persistent reservoir of cells latently infected with human immunodeficiency virus (HIV)-integrated proviral DNA necessitates lifelong suppressive antiretroviral therapy (ART). Epigenetic targeted compounds have shown promise as potential latency-reversing agents; however, these drugs have undesirable toxicity and lack specificity for HIV. We utilized a novel HEK293-derived FlpIn dual-reporter cell line, which quantifies specific HIV provirus reactivation (LTR promoter) relative to nonspecific host cell gene expression (CMV promoter), to identify the 5-substituted 2-acylaminothiazole hit class. Here, we describe the optimization of the hit class, defining the functionality necessary for HIV gene activation and for improving in vitro metabolism and solubility. The optimized compounds displayed enhanced HIV gene expression in HEK293 and Jurkat 10.6 latency cellular models and increased unspliced HIV RNA in resting CD4+ T cells isolated from HIV-infected individuals on ART, demonstrating the potential of the 2-acylaminothiazole class as latency-reversing agents.

  DOI：

  10.1021/acs.jmedchem.9b00462
• 作为产物：
  描述：

  4-(4-benzyloxy-phenoxy)-butyric acid ethyl ester 在 5% palladium-on-charcoal 氢气 作用下， 以 乙醇 为溶剂， 以1.97 g的产率得到4-(4-hydroxy-phenoxy)-butyric acid ethyl ester
  参考文献：
  名称：

  Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors

  摘要：

  该公式的化合物可用于治疗由TNF-α介导的疾病状况，例如类风湿性关节炎、骨关节炎、脓毒症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和退化性软骨丧失。

  公开号：

  US06340691B1

文献信息

• [EN] CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY<br/>[FR] INHIBITEURS DES KINASES DÉPENDANTES DES CYCLINES (CDK) CONTENANT UNE FRACTION DE LIAISON AU ZINC
  申请人：CURIS INC

  公开号：WO2009036016A1

  公开（公告）日：2009-03-19

  The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The compounds of the invention may further act as HDAC inhibitors.

  本发明涉及CDK抑制剂及其在治疗癌症等细胞增殖性疾病中的应用。该发明的化合物还可能作为HDAC抑制剂。
• Heterocyclic compouds
  申请人：Zeneca Limited

  公开号：US05753659A1

  公开（公告）日：1998-05-19

  A compound of the general formula (M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I wherein: n is 0 or 1; M.sup.1 is an amino group; Q is an aromatic heterocyclic group containing a basic nitrogen atom; M.sup.2 is an imino group; L is a template group; and A is an acidic group, or an ester or amide derivative thereof, or a sulphonamide group; and pharmaceutically acceptable salts and pro-drugs thereof, for use in the treatment of a disease in which platelet aggregation mediated by the binding of adhesion molecules to GPIIb-IIIa is involved. Novel compounds are also disclosed.

  通式（M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I的化合物，其中：n为0或1；M.sup.1为氨基；Q为含有碱性氮原子的芳香杂环基团；M.sup.2为亚胺基；L为模板基团；A为酸性基团，或其酯或酰胺衍生物，或磺酰胺基团；以及其药学上可接受的盐和前药，用于治疗通过粘附分子结合到GPIIb-IIIa介导的血小板聚集参与的疾病。还披露了新的化合物。
• Phosphinyloxy propanaminium inner salt derivatives
  申请人：Sandoz Ltd.

  公开号：US05516767A1

  公开（公告）日：1996-05-14

  Compounds of the formula ##STR1## where X.sub.1 and X.sub.2 are independently O or S, and R.sub.1 is as defined in the description R.sub.2, R.sub.3, and R.sub.4 are each independently straight or branched chain (C.sub.1-4)alkyl, and pharmaceutically acceptable salts, physiological hydrolysable esters, and pro-drug forms thereof are useful as hypoglycemic agents.

  式为##STR1##的化合物，其中X.sub.1和X.sub.2分别为O或S，R.sub.1如描述中所定义，R.sub.2、R.sub.3和R.sub.4各自独立地为直链或支链(C.sub.1-4)烷基，以及其药学上可接受的盐、生理可水解酯和前药形式可用作降血糖药物。
• Process for preparing phosphinyloxy propanaminium inner salt derivatives
  申请人：Sandoz Ltd.

  公开号：US05412137A1

  公开（公告）日：1995-05-02

  A process for preparing compounds of the formula ##STR1## where X.sub.1 and X.sub.2 are independently O or S, and R.sub.1 is as defined herein, R.sub.2, R.sub.3, and R.sub.4 are each independently straight or branched chain (C.sub.1-4)alkyl, and pharmaceutically acceptable salts, physiological hydrolyzable esters, and pro-drug forms thereof, which are useful as hypoglycemic agents.

  制备化合物的方法，化合物的结构式为##STR1## 其中X.sub.1和X.sub.2分别独立地为O或S，R.sub.1如本文所定义，R.sub.2、R.sub.3和R.sub.4分别独立地为直链或支链(C.sub.1-4)烷基，以及其药用盐、生理可水解酯和前药形式，这些化合物可用作降糖药物。
• General Method for the Synthesis of Salicylic Acids from Phenols through Palladium-Catalyzed Silanol-Directed CH Carboxylation
  作者：Yang Wang、Vladimir Gevorgyan

  DOI：10.1002/anie.201410375

  日期：2015.2.9

  silanol‐directed, palladium‐catalyzed CH carboxylation reaction of phenols to give salicylic acids has been developed. This method features high efficiency and selectivity, and excellent functional‐group tolerance. The generality of this method was demonstrated by the carboxylation of estrone and by the synthesis of an unsymmetrically o,o′‐disubstituted phenolic compound through two sequential CH functionalization

  已经开发出一种硅烷醇引导、钯催化的苯酚 C → H 羧化反应，生成水杨酸。该方法具有高效、选择性高、官能团耐受性好的特点。该方法的通用性通过雌酮的羧化和通过两个连续的C - H官能化过程合成不对称o , o'-二取代酚类化合物得到证明。